Ribociclib | List of Frontiers open access articles

Original Research

Published on 31 Mar 2025

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

in Drug Metabolism and Transport

Zihan Liu
Wenyu Du
Qimin Wang
Zhi Wang
Jing An
Yinling Ma
Zhanjun Dong
Ying Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1530806

3,211 views
2 citations

Original Research

Published on 24 May 2022

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

in Thoracic Oncology

Yuan Ke
Cheng-Gong Liao
Zheng-Qing Zhao
Xiao-Min Li
Rong-Jie Lin
Long Yang
He-Long Zhang
Ling-Min Kong

Frontiers in Oncology

doi 10.3389/fonc.2022.880153

4,993 views
7 citations

Original Research

Published on 07 May 2021

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

in Women's Cancer

Eunae Jeong
Changjun Wang
Leslie Wilson
Lixian Zhong

Frontiers in Oncology

doi 10.3389/fonc.2021.658054

8,746 views
14 citations

Original Research

Published on 01 Apr 2022

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells

in Pharmacology of Anti-Cancer Drugs

Lei Zhang
Biwei Ye
Yunfeng Lin
Yi-Dong Li
Jing-Quan Wang
Zhuo Chen
Feng-Feng Ping
Zhe-Sheng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2022.867128

5,131 views
8 citations

Original Research

Published on 01 Jul 2024

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database

in Pharmacology of Anti-Cancer Drugs

Jinhua Chen
Linlin Tang
Wenping Song
Cuicui Sun
Wenzhou Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1371346

4,064 views
1 citation

Original Research

Published on 15 Dec 2023

The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

in Breast Cancer

Nour Hisham Al-Ziftawi
Shereen Elazzazy
Mohammed Fasihul Alam
Asrul Shafie
Anas Hamad
Salha Bbujassoum
Mohamed Izham Mohamed Ibrahim

Frontiers in Oncology

doi 10.3389/fonc.2023.1203684

9,512 views
19 citations

Original Research

Published on 24 Jul 2024

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

in Breast Cancer

Shereen Elazzazy
Nour Hisham Al-Ziftawi
Mohamed Izham Mohamed Ibrahim
Salha Bujassoum
Anas Hamad

Frontiers in Oncology

doi 10.3389/fonc.2024.1413676

6,405 views
7 citations

Case Report

Published on 08 Nov 2022

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report

in Breast Cancer

Francesco Schettini
Elia Seguí
Benedetta Conte
Esther Sanfeliu
Blanca Gonzalez-Farre
Pedro Jares
Sergi Vidal-Sicart
Sergi Ganau
Isaac Cebrecos
Fara Brasó-Maristany

Frontiers in Oncology

doi 10.3389/fonc.2022.1009352

5,702 views
10 citations

Case Report

Published on 24 Aug 2023

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation

in Breast Cancer

Jyun-Yan Jhan
Wei-En Wang
Sung-Chao Chu
Chiu-Hsuan Cheng
Chung-Hsing Chang

Frontiers in Oncology

doi 10.3389/fonc.2023.1184738

4,486 views
3 citations

Case Report

Published on 08 Jun 2023

Ribociclib in newly diagnosed hepatitis B infection: A case report

in Breast Cancer

Fabrizio Di Costanzo
Simone Carrano
Gennaro Iengo
Amedeo Cefaliello
Valentina Cossiga
Filomena Morisco
Mario Giuliano
Carmine De Angelis
Grazia Arpino

Frontiers in Oncology

doi 10.3389/fonc.2023.1184952

3,601 views
1 citation

Original Research

Published on 09 Feb 2022

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

in Breast Cancer

Andrea Botticelli
Agnese Fabbri
Michela Roberto
Daniele Alesini
Alessio Cirillo
Giuliana D’Auria
Eriseld Krasniqi
Eleonora Marrucci
Margherita Muratore
Francesco Pantano

Frontiers in Oncology

doi 10.3389/fonc.2022.797157

7,077 views
3 citations

Case Report

Published on 08 Dec 2025

Vitiligo associated with ribociclib therapy: a rare case report

in Breast Cancer

Zirui Wang
Yuanrui Bai
Rihan Wu
Yihui Liu
Chunhui Dong
Ling Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1669407

1,448 views
1 citation

Case Report

Published on 19 Dec 2024

Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports

in Breast Cancer

Tamara Martos
Marta Saint-Gerons
Laura Masfarre
Maria Castro-Henriques
Maria Martinez-Garcia
Sonia Servitja
Joan Albanell

Frontiers in Oncology

doi 10.3389/fonc.2024.1430341

2,486 views

Clinical Trial

Published on 19 Mar 2019

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck

in Head and Neck Cancer

Emmanuel Seront
Sandra Schmitz
Matthias Papier
Aline van Maanen
Stéphanie Henry
Christophe Lonchay
Sylvie Rottey
Gabrielle van Caloen
Jean-Pascal Machiels

Frontiers in Oncology

doi 10.3389/fonc.2019.00155

3,829 views
22 citations

Original Research

Published on 03 Apr 2024

CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug–gene interaction network

in Pharmacoepidemiology

Youjun She
Zihan Guo
Qing Zhai
Jiyong Liu
Qiong Du
Zhongwei Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1378090

11,677 views
16 citations

Original Research

Published on 16 Jan 2026

Multi-omics integration and machine learning identify NPC2 as a prognostic and treatment-responsive regulator in lung adenocarcinoma

in Cancer Immunity and Immunotherapy

Ang Li
Ping Cui
Lili Liu
Jiawei Liu
Xianlei Zhou
Wenlong Wu
Zimo Yan
Yi Guan
Hongmei Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1697560

1,122 views
1 citation

Articles

In Vivo pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells

Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database

The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report

Case Report: Ribociclib-induced phototoxicity presented as dyschromia with subsequent bullae formation

Ribociclib in newly diagnosed hepatitis B infection: A case report

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

Vitiligo associated with ribociclib therapy: a rare case report

Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports

Phase 1 Study Evaluating the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib and Cetuximab in Recurrent/Metastatic p16-Negative Squamous Cell Carcinoma of the Head and Neck

CDK4/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug–gene interaction network

Multi-omics integration and machine learning identify NPC2 as a prognostic and treatment-responsive regulator in lung adenocarcinoma